Molecular Oncology Diagnostics Market to Grow with a CAGR of 14.17% through 2030
Increased prevalence of
cancer and protein transformation in biomarker identification are expected to
drive the growth of Global Molecular Oncology Diagnostics Market during the
forecast period, 2026-2030.
According to
TechSci Research report, “Molecular
Oncology Diagnostics Market - Global Industry Size, Share, Trends, Competition,
Opportunity, and Forecast, 2030,” the
Global
Molecular Oncology Diagnostics Market stood at USD 3.54 billion in 2024 and is anticipated to grow with a CAGR of 14.17% in the forecast period through 2030. Cancer
is one of the most diagnosed diseases in the world. According to Global
Cancer Statistics 2021, around 1.9 million new instances of cancer were
expected to have been diagnosed.
However,
stringent regulatory scenario related to high cost of diagnostics procedures,
and side effects associated with imaging and the lack of awareness of early
diagnosis are likely to slow down the market growth in the coming years. Also, lack
of skilled professionals to conduct sensitive surgeries/biopsy pertaining to cancer
treatment especially in the emerging countries can further slowdown the market
growth.
In addition, the pipeline of innovative diagnostic products is expanding rapidly, with numerous biotechnology and diagnostic companies focusing on the development of high-throughput, cost-effective, and user-friendly solutions. The integration of artificial intelligence and bioinformatics tools in molecular oncology diagnostics is further enhancing the accuracy and speed of data interpretation, allowing for more informed clinical decision-making. Furthermore, global health authorities and governments are increasingly investing in cancer control initiatives, genomic research, and public screening programs, which is expected to strengthen the demand for molecular oncology diagnostics. As regulatory pathways for diagnostic products become more streamlined, especially in emerging economies, the adoption of these technologies is likely to accelerate across diverse healthcare settings.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global Molecular Oncology Diagnostics Market”
Global
Molecular Oncology Diagnostics Market is segmented into product type, technology, application,
cancer type, end user, regional distribution and company.
Based on Product Type, the Software category is experiencing the fastest growth among all product types. This surge in demand is primarily fueled by the increasing reliance on bioinformatics tools, data analytics platforms, and machine learning algorithms to manage, interpret, and visualize the complex genomic data generated during molecular diagnostic procedures. As oncology diagnostics become increasingly sophisticated—with techniques such as next-generation sequencing (NGS), digital PCR, and high-throughput gene expression analysis, the volume and complexity of genomic data have grown exponentially. This has necessitated the development and integration of advanced software solutions to handle tasks such as mutation calling, variant interpretation, biomarker identification, and patient stratification. These tools are not only improving diagnostic accuracy but also facilitating personalized treatment planning, thereby enhancing clinical outcomes.
Based on the Region, The Asia-Pacific (APAC) region is emerging as the fastest-growing market for molecular oncology diagnostics, driven by a surge in cancer incidence, increasing healthcare investments, rising awareness about early cancer detection, and ongoing improvements in healthcare infrastructure. Countries such as China, India, Japan, South Korea, and Australia are leading this growth trajectory through initiatives that support molecular testing for cancer and the integration of precision medicine into national healthcare systems. According to the World Health Organization (WHO), the Asia-Pacific region accounted for nearly 49% of all new global cancer cases in 2022, with China and India together contributing a significant proportion of this burden. For instance, India’s National Cancer Registry Programme estimated over 1.46 million new cancer cases in 2022, with projections indicating a rise to 1.57 million cases by 2025. This mounting disease burden is fueling demand for advanced molecular diagnostics to enable early detection, targeted therapy selection, and disease monitoring.
The leading companies operating in the Global
Molecular Oncology Diagnostics Market are:
- Sysmex Corporation
- F. Hoffmann-La Roche Ltd.
- Myriad Genetics, Inc.
- HTG Molecular Diagnostics, Inc.
- Danaher Corporation
- QIAGEN N.V.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Illumina, Inc.
- Bayer AG
Download Free Sample Report
Customers can also request for 10% free
customization on this report.
“The market is poised for substantial growth in the coming years, driven by a confluence of technological advancements, increasing cancer prevalence, and a growing emphasis on personalized medicine. As healthcare systems worldwide shift toward precision-based approaches, molecular diagnostics are becoming integral to oncology for their ability to detect cancer at earlier stages, identify specific genetic mutations, and guide targeted therapies. The market is experiencing strong momentum due to rising awareness among healthcare providers and patients about the benefits of molecular diagnostics in improving treatment outcomes. Increasing availability of advanced diagnostic platforms such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH) is transforming how clinicians diagnose and manage various cancer types, including breast, lung, colorectal, and hematological malignancies. Additionally, high market penetration rate
of technologically advanced diagnostic products is expected to increase the
demand for Global Molecular Oncology Diagnostic Market in the coming years”, said
Mr. Karan Chechi, Research Director of TechSci Research, a research based global
management consulting firm.
“Molecular Oncology Diagnostics Market -
Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product Type
(Instruments, Kits and Assays, Software), By Technology (Fluorescence In-Situ
Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain
Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other
Technologies), By Application (Research, Clinical), By Cancer Type ({Solid
Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal
Cancer, and Other Solid Tumors), Blood Cancers (Lymphoma, Leukemia, Multiple
Myeloma, and other Hematological Malignancies)}, By End User (Hospitals and
Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology
Companies, Academic and Research Institutes), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Molecular Oncology Diagnostics Market and provides statistics & information
on market size, structure, and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in Global
Molecular Oncology Diagnostics Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com